Back to top
more

IDEXX Laboratories (IDXX)

(Real Time Quote from BATS)

$658.71 USD

658.71
413,517

+8.65 (1.33%)

Updated Aug 8, 2025 03:55 PM ET

After-Market: $658.67 -0.04 (-0.01%) 4:12 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (145 out of 244)

Industry: Medical - Instruments

Zacks News

Zacks Equity Research

Here's Why You Should Add Hill-Rom (HRC) to Your Portfolio

Investors continue to be optimistic about robust demand for Hill-Rom's (HRC) product as well as its solid first-quarter fiscal 2021 results.

Zacks Equity Research

IDEXX Laboratories (IDXX) Sees Hammer Chart Pattern: Time to Buy?

IDEXX Laboratories (IDXX) has been struggling lately, but the selling pressure may be coming to an end soon

Zacks Equity Research

Here's Why You Should Add McKesson (MCK) to Your Portfolio Now

McKesson (MCK) continues to benefit from multi-year strategic growth initiative and Distribution Solutions segment.

Zacks Equity Research

Here's Why You Should Retain Cardinal Health (CAH) Stock Now

Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment and diversified product portfolio.

Zacks Equity Research

PerkinElmer (PKI) Boosts Testing Portfolio With New Solutions

PerkinElmer's (PKI) introduction of two comprehensive solutions is likely to strengthen its COVID-19 testing portfolio further.

Zacks Equity Research

BD (BDX), ImageMover Partner for Rapid Antigen Test Reporting

BD (BDX) collaborates with ImageMover to streamline rapid antigen testing results performed on the BD Veritor Plus System.

Zacks Equity Research

Hologic (HOLX) Partners With Gallup on Women's Health Index

Hologic (HOLX) is working to develop a global women's health index through Gallup's World Poll to improve quality of life and life expectancy of women worldwide.

Zacks Equity Research

Abbott (ABT) Launches Telehealth Tool for Neuromodulation

Abbott (ABT) stated that Medicare will cover remote programming services as a telehealth benefit through the duration of the public health emergency.

Zacks Equity Research

QIAGEN (QGEN) Rides on Test Launches Amid COVID-19 Woes

QIAGEN (QGEN) expands specimen types that can be used on the existing NeuMoDx SARSCoV-2 test.

Zacks Equity Research

Myriad Genetics (MYGN) Collaborates to Advance Oncology Care

Myriad Genetics (MYGN) to provide a comprehensive offering utilizing germline genetic testing and somatic tumor profiling via latest collaboration with Intermountain Precision Genomics.

Zacks Equity Research

Why Is Idexx (IDXX) Up 2.6% Since Last Earnings Report?

Idexx (IDXX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

National Vision (EYE) Q4 Earnings Top Estimates, Margins Up

National Vision (EYE) witnesses comparable growth on increased customer transaction in Q4.

Zacks Equity Research

Medtronic's (MDT) REVERSE Trial Indicates CRT's Benefits for HF

Medtronic's (MDT) REVERSE analysis highlights the role played by CRT to slow the progression of HF, thus reinforcing the strong clinical evidence supporting CRT.

Zacks Equity Research

Here's Why You Should Hold on to Medtronic (MDT) Stock for Now

Investors continue to be optimistic about Medtronic (MDT) on slew of product launches and regulatory approvals.

Zacks Equity Research

Is IDEXX Laboratories (IDXX) Outperforming Other Medical Stocks This Year?

Is (IDXX) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

Hologic (HOLX) Boosts Diagnostics Portfolio With New Buyout

Hologic (HOLX) strengthens international capabilities and expands diagnostics arm across test menu, customer segments and geography with recent acquisition.

Zacks Equity Research

Here's Why You Should Add Abbott (ABT) to Your Portfolio

Investors continue to be optimistic about Abbott (ABT) due to a slew of product launches and regulatory approvals.

Zacks Equity Research

Orthofix's (OFIX) Q4 Earnings Top Estimates, Margin Declines

Orthofix (OFIX) registers improvement in Global Spine segment's revenues during Q4 due to strength in its spinal implants portfolio.

Zacks Equity Research

Teleflex (TFX) Beats on Q4 Earnings and Revenues, Margins Fall

Teleflex (TFX) witnesses significant sequential improvement in segmental performance during the fourth quarter on gradual recovery of the economy.

Zacks Equity Research

NuVasive's (NUVA) Q4 Earnings Top Estimates, Margin Declines

NuVasive (NUVA) registers strong international performance in Q4 along with continued adoption of advanced material science implants in the U.S. Spinal Hardware business.

Zacks Equity Research

Tandem Diabetes' (TNDM) Q4 Earnings, Revenues Top Estimates

Tandem Diabetes' (TNDM) strong domestic and international pump sales and shipments boosted the Q4 top line.

Zacks Equity Research

Myriad Genetics (MYGN) Beats on Q2 Revenues, Earnings in Line

Myriad Genetics' (MYGN) sales in majority of the operating segments improved in the quarter despite pandemic-led business challenges.

Zacks Equity Research

Insulet (PODD) Q4 Earnings Fall Shy of Estimates, Revenues Beat

Insulet's (PODD) Q4 revenues were significantly boosted by the robust adoption of Omnipod DASH and a growing customer base.

Zacks Equity Research

BD (BDX), Scanwell Health Collaborate on At-Home Coronavirus Test

BD (BDX) plans to develop a lateral flow antigen test and pair it with the Scanwell Health mobile app via the latest partnership.

Zacks Equity Research

Here's Why You Should Add Hologic (HOLX) to Your Portfolio

Investors continue to be optimistic about Hologic (HOLX) due to a slew of product launches.